Phaseline

Companies › Sonoma Biotherapeutics

Sonoma Biotherapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SBT777101–Phase 1Hidradenitis Suppurativa; Rheumatoid ArthritisNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06361836SBT777101Phase 1Hidradenitis SuppurativaImmunologyNov 2026
NCT06201416SBT777101Phase 1Rheumatoid ArthritisImmunologyNov 2026

From the company's SEC filings

Cash of $5m on 2026-06-30; operating cash outflow about $3m a year; runway about 24 months at that burn, to Jul 2028

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.